The pharmaceutical giant, whose China chief is now under investigation, was previously at the centre of insurance scam cases, ...
The AstraZeneca PLC ADR AZN inched 0.01% higher to $71.43 Monday, on what proved to be an all-around grim trading session ...
The Big Pharma companies made a last-ditch effort asking a U.S. appeals court to reconsider their lawsuits against the ...
AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety ...
AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.
UBS analyst Matthew Weston maintained a Sell rating on AstraZeneca (AZN – Research Report) today and set a price target of £113.00. The ...
As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD. | As AstraZeneca ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...
AstraZeneca said its China president Leon Wang is under investigation and the drugmaker would cooperate with Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback